Результаты поиска

Curcumin as a complementary treatment in oncological therapy: a systematic review.

PurposeCurcumin, the active ingredient in turmeric, is employed by numerous cancer patients to support conventional cancer therapy. This systematic review aims to summarize the existing clinical evidence and to provide an overview of the potential benefits and risks associated with curcumin supplementation.MethodsIn January 2024, we conducted a systematic search of five electronic databases (Embase, Cochrane, PsycInfo, CINAHL, and Medline) using a complex search strategy. We included randomized controlled trials on the use, effectiveness, and potential harm of additional curcumin therapy in ad

Всеобъемлющий и систематический обзор по вопросу о добавке ресвератрола в качестве перспективного кандидата в отношении болезни сетчатки сетчатки: акцент на механизмах действий на основе доклинических исследований.

Resveratrol — естественный полифенолический соединение, демонстрирующее большой потенциал нейрозащиты, борьбы с воспалением и антиоксидацией. Предыдущие исследования показали, что ресвератрол может эффективно лечить различные животные модели болезней сетчатки. ПУРПОСЕ: Цель исследования состояла в том, чтобы использовать экспериментальную модель животных для оценки эффективности лечения заболеваний, связанных с сетчаткой, в рамках различных видов заболеваний, связанных с животным, таких, как ишемия-реперциозная травма, диабетическая ретинопатия, глаукома, хроническая окулярная гипертония, опти

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia.

Myelodysplastic Syndromes (MDSs) affect the elderly and can progress to Acute Myeloid Leukemia (AML). Epigenetic alterations including DNA methylation and chromatin modification may contribute to the initiation and progression of these malignancies. DNA hypomethylating agents such as decitabine and azacitidine are used as therapeutic treatments and have shown to promote expression of genes involved in tumor suppression, apoptosis, and immune response. Another anti-cancer drug, the proteasome inhibitor bortezomib, is used as a chemotherapeutic treatment for multiple myeloma (MM). Phase III clin

Учебный протокол: Исследовательный эксперимент на базе осмотина в качестве адъютанта для лечения прогрессивного множественного склероза.

ЦЕЛЬ: Множественный склероз (MS) является первой причиной нетравматических неврологических расстройств у молодых людей. Первичные и вторичные прогрессивные MS по-прежнему не имеют эффективных методов лечения. Недавно был разработан новый продукт, изготовленный из листьев листьев биоинженерных киви (Actinidia deliciosa), перевыражающих осмотин. Осмотин — белок, связанный с адаптацией к стрессу в растительных клетках, и он обладает противовоспалительными и нейрозащитными свойствами с адипонектином млекопитающих. Цель этого исследования заключается в изучении вопроса о безопасности и эффективност

Solitary osseous plasmacytomas in dogs: 13 cases (2004-2019).

ObjectivesTo further characterise solitary osseous plasmacytoma in dogs, an extremely rare disease. To describe diagnosis, disease progression and treatment outcomes in dogs with solitary osseous plasmacytoma.Materials and methodsRetrospective review of dogs with solitary osseous plasmacytomas that were diagnosed and treated at a single institution from 2005 to 2019. Kaplan-Meier single group survival analysis was used to estimate median survival time and progression-free interval.ResultsThirteen dogs met the inclusion criteria for the study, and of those, 11 were treated. The median age at di

Adequate IVIG dosing is associated with an improved long-term outcome in secondary immunodeficiency: A prospective, non-interventional study.

OBJECTIVE: To assess the safety, tolerability, and effectiveness of the intravenous immunoglobulin (IVIG) Intratect 50 g/L in immunoglobulin replacement therapy (IgRT) in a prospective, large-scale non-interventional study (NIS). The analysis focused upon patients with secondary immunodeficiency (SID), the most frequent indication for IgRT in this NIS. MATERIALS AND METHODS: Patients were enrolled at 123 centers in Germany. Each patient received IVIG as prescribed by the physician, guided by the Summary of Product Characteristics. Data were acquired from medical records and patients' question

Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities.

Optimal control theory is branch of mathematics that aims to optimize a solution to a dynamical system. While the concept of using optimal control theory to improve treatment regimens in oncology is not novel, many of the early applications of this mathematical technique were not designed to work with routinely available data or produce results that can eventually be translated to the clinical setting. The purpose of this review is to discuss clinically relevant considerations for formulating and solving optimal control problems for treating cancer patients. Our review focuses on two of the mo

Computed tomography with low-dose radiation versus standard-dose radiation for diagnosing fractures: systematic review and meta-analysis.

BackgroundComputed tomography (CT) accounts for 13% of all radiological examinations in the United States and 40-70% of the radiation that patients receive. Even with the advent of magnetic resonance imaging (MRI), CT continues to be the gold standard for diagnosing bone fractures. There is uncertainty as to whether CT with a low radiation dose has a fracture detection rate similar to that of standard-dose CT.ObjectiveTo determine the detection rate of low-dose radiation CT and standard-dose radiation CT for fractures, in patients with suspected fractures.Design and settingSystematic review of

VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia.

VEXAS syndrome stands for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome. The syndrome is a combined hematological and rheumatological condition caused by a somatic mutation in the UBA1. There is an association between VEXAS and hematological conditions such as myelodysplastic syndrome (MDS), monoclonal gammopathies of uncertain conditions (MGUS), multiple myeloma (MM), and monoclonal B-cell lymphoproliferative conditions. There are not many descriptions of patients having VEXAS in combination with myeloproliferative neoplasm (MPN). With this article, we want to present a ca

Guidelines for the management of osteoporosis and fragility fractures.

The purpose of this document, a result of the harmonisation and revision of Guidelines published separately by the SIMFER, SIOMMMS/SIR, and SIOT associations, is to provide practical indications based on specific levels of evidence and various grades of recommendations, drawn from available literature, for the management of osteoporosis and for the diagnosis, prevention, and treatment of fragility fractures. These indications were discussed and formally approved by the delegates of the Italian Scientific Associations involved in the project (SIE, SIGG, SIMFER, SIMG, SIMI, SIOMMMS, SIR, and SIO

Unlocking the Potential of Ganoderma lucidum (Curtis): Botanical Overview, Therapeutic Applications, and Nanotechnological Advances.

Background:Ganoderma lucidum (GL), commonly known as the "Lingzhi" or "Reishi" mushroom, has long been recognized for its potential health benefits and medicinal properties in traditional Chinese medicine. The unique potential combination of bioactive compounds present in GL, such as triterpenoids, polysaccharides, and peptides, has inspired interest in leveraging their therapeutic potential In recent years, the emerging field of nanotechnology has opened up new possibilities for using the remarkable properties of GL at the nanoscale. Objetive: The main objective of this review is to explore t

Совпадение в полном тексте источника
… Dosage Forms and Posology GL can be prepared in various dosage forms and consumed on different routes. The appropriate dosage and posology of GL may depend on factors such as the specific formulation, the individual’s age, overall health, and the intended purpose of use. … Table 3 Gonaderma lucidum dosage forms and posology available [ 21 , 83 ]. Dosage Forms | Posology Tablets or Capsules | 1–3 capsules/tablets of GL per day. Powder | 1–3 g of GL powder per day. Extracts | Can vary depending on the concentration and potency of the extract. …

Availability, price and affordability of anticancer medicines in Jiangsu Province, China: a cross-sectional survey study.

BackgroundTo evaluate anticancer medicines' availability, price and affordability in nine prefecture-level cities, Jiangsu Province.MethodsBased on the standard methods recommended by the World Health Organization (WHO) and the Health Action International (HAI), a cross-sectional survey was performed to collect information about 24 essential anticancer medicines (EAMs) and 17 innovative anticancer medicines (IAMs) in hospitals and 45 community pharmacies in Jiangsu Province from July to November 2021.ResultsIn general, the availability of EAMs during the study period was higher than that of IA

Совпадение в полном тексте источника
… Notably, no statistically significant regional differences were observed in the availability of novel anticancer agents in retail pharmacies, potentially due to the convenience and portability of oral dosage forms. … In contrast, novel anticancer drugs showed comparable availability between the two channels—a discrepancy that may be linked to differences in dosage forms. …

Comparative Study of Recombinant Human Erythropoietin (rhEPO) Products on CKD (Chronic Kidney Disease) Patients.

PurposeThis study was conducted to evaluate whether the efficacy and safety profile of recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd was similar to biological products approved by the drug safety regulatory authority.Patients and methodsIt was an open-label, randomized, comparative, parallel, multi-center study in hemodialysis patients with anemia. The reference product at an individualized dose 3 times a week was given in 4-8 weeks of titration period and hemoglobin (Hb) level was controlled to reach the range of 10-12 g/dL. Then, the subjects were

Стойкость к Ocrelizumab по сравнению с другими лекарственными препаратами для нескольких склерозов: результаты немецкого регистра нейротрансфер данных.

ВВЕДЕНИЕ: Устойчивость лечения имеет решающее значение для получения полного терапевтического пособия и может указывать на благоприятные результаты. В рамках этого исследования изучался вопрос о стойкости в реальном мире к воздействию острелизумаба (ОКР) в сравнении с другими методами лечения, позволяющими видоизменить заболевания (ДМТ), и его связь с результатами повторного выброса нескольких склерозов (РРМС) с использованием данных немецкого реестра нейротрансданных (НТД). МЕТОДЫ: Этот ретроспективный когортный анализ охватывал амбулаторных больных, которые с января инициировали ДМТ 2014 и а

Assessment of the availability of repurposed orphan drugs in India.

India has a massive burden of rare diseases (RDs), with an estimated 96 million people living with RDs but limited options for treatment. Repurposing drugs used for other common conditions are essential alternative for RDs due to their cost-effectiveness and reduced timeline. India's patent regime prevents the evergreening of drugs, and a large generic manufacturing industry provides ample opportunity to explore the potential of repurposed drugs for treating RDs, known as repurposed orphan drugs (ROD). However, there is no portal or other source for information on orphan drugs in India. This s

Совпадение в полном тексте источника
… There is also a provision for ‘Subsequent new drug application’ for approval of an already approved new drug (within 4 years), with new claims, namely, indications, dosage, dosage form, and route of administration [ 10 ]. NPRD also supports research for repurposing drugs [ 2 ]. … A1.4: In the case of Cytarabine and daunorubicin citrate , both drugs were available in separate dosage forms but daunorubicin citrate was available as daunorubicin in the CDSCO list. …

Systemic lupus erythematosus: pathogenesis and targeted therapy.

Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by dysregulated immune responses and autoantibody production, which affects multiple organs and varies in clinical presentation and disease severity. The development of SLE is intricate, encompassing dysregulation within the immune system, a collapse of immunological tolerance, genetic susceptibilities to the disease, and a variety of environmental factors that can act as triggers. This review provides a comprehensive discussion of the pathogenesis and treatment strategies of SLE and focuses on the progress

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.

Hairy cell leukaemia (HCL) is a rare haematological malignancy, with approximately 175 new incident cases in France. Diagnosis is based on a careful examination of the blood smear and immunophenotyping of the tumour cells, with a panel of four markers being used specifically to screen for hairy cells (CD11c, CD25, CD103 and CD123). In 2011, the V600E mutation of the BRAF gene in exon 15 was identified in HCL; being present in HCL, it is absent in the variant form of HCL (HCL-v) and in splenic red pulp lymphoma (SRPL), two entities related to HCL. The management of patients with HCL has changed

Hematopoietic Tumors

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

ESCP 36th European Symposium on Clinical Pharmacy ‘Implementing Clinical Pharmacy in Community and Hospital Settings: Sharing the Experience’, Istanbul, Turkey 25–27 October 2007; Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.

PURPOSE: Pegylated liposomal doxorubicin (PLD) is highly effective for treating multiple myeloma (MM). Hand-foot syndrome (HFS) is a dose-limiting adverse event of PLD that may reduce a patient's quality of life or prevent certain patients from receiving PLD. Several researchers have discovered that pyridoxine, an activated form of vitamin B6, may prevent PLD-associated HFS. We designed a prospective randomized trial to examine whether prophylactic pyridoxine might prevent the incidence or delay the occurrence of PLD-induced HFS in patients with MM. METHODS: Patients who met the trial's eligi